{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:32:31Z","timestamp":1792423951934,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This multicenter, single-arm, phase 1\/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric antigen receptor (CAR) immunotherapy CTX110 in adult patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL). Patients received 1 or 2 treatment courses: standard lymphodepletion, followed by 1 CTX110 infusion at dose levels (DLs) 1 to 4 (3 \u00d7 107 to 60 \u00d7 107 CAR T cells; dose escalation, N = 32), or 2 infusions at DL4 on days 1 and 35 (cohort expansion, N = 31). Primary end points in dose escalation and cohort expansion were incidence of dose-limiting toxicities and objective response rate, respectively. CTX110 was administered to 63 heavily pretreated patients: 59% primary refractory, 43% with \u22653 previous therapies. Among 57 patients whose first infusion was DL \u22653, rates of objective and complete response (CR) were 65% and 39%, respectively. Among 22 patients achieving CR, 5 (23%) had ongoing CR at data cutoff, with 15 to 50 (median 34) months follow-up. The 2-infusion regimen prolonged response duration vs 1 infusion (hazard ratio, 0.65). Cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) were reported in 54% and 13% of treated patients, respectively, including 2 grade \u22653 cases each. The most common grade \u22653 adverse events (AEs) were neutropenia (59%), and anemia and thrombocytopenia (35% each). Serious AEs occurred in 32% of treated patients, including CRS (14%), ICANS (8%), and febrile neutropenia (6%). In this R\/R NHL population, CTX110 was well tolerated, resulting in clinically meaningful responses at DL \u22653, with a second infusion demonstrating further clinical benefit. This trial was registered at www.clinicaltrials.gov as #NCT04035434.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020123","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:54:44Z","timestamp":1778010884000},"page":"5778-5788","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed\/refractory B-cell non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, The University of Kansas Cancer Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-8474","authenticated-orcid":false,"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[{"name":"2Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Bachier","sequence":"additional","affiliation":[{"name":"3Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, Health Corporation of America Healthcare, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"3Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, Health Corporation of America Healthcare, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Maakaron","sequence":"additional","affiliation":[{"name":"5Blood and Marrow Transplant Program of Georgia, Northside Hospital, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-9273","authenticated-orcid":false,"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[{"name":"6David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"7Institute of Haematology, Royal Prince Alfred Hospital and The University of Sydney, Camperdown, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"8Alfred Hospital and Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-5966","authenticated-orcid":false,"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"9Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Darrah","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6729","authenticated-orcid":false,"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-4248","authenticated-orcid":false,"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[{"name":"13Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley","family":"Ross","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Williams","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Pan","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Stevens","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Serwer","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Nguyen","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Terrett","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Kalaitzidis","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ma","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huansheng","family":"Xu","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Benton","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Weaver","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Beaussant","family":"Cohen","sequence":"additional","affiliation":[{"name":"14CRISPR Therapeutics, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"15Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan","family":"Cheah","sequence":"additional","affiliation":[{"name":"16Division of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"5","key":"2026090811321228300_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.2015.1023712","article-title":"New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy","volume":"15","author":"Chihara","year":"2015","journal-title":"Exp Rev Anticancer Ther"},{"issue":"21","key":"2026090811321228300_bib2","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood.V120.21.5074.5074","article-title":"Epidemiology projection trends for non-Hodgkin lymphoma (NHL) and its subtypes in the United States (US) and Europe (EU)","volume":"120","author":"Trask","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2026090811321228300_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"5-6","key":"2026090811321228300_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"suppl 13","key":"2026090811321228300_bib5","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.37765\/ajmc.2021.88737","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am J Manag Care"},{"issue":"suppl 1","key":"2026090811321228300_bib6","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2024-208283","article-title":"Treatment patterns and predictors of survival after first line therapy in large B-cell lymphoma in a real-world US cohort","volume":"144","author":"McGuirk","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026090811321228300_bib7","first-page":"714","article-title":"Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026090811321228300_bib8","first-page":"S391","article-title":"Real-world treatment patterns of large B-cell lymphoma patients over time in a post-CAR T approval era","volume":"31","author":"Perales","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"suppl 1","key":"2026090811321228300_bib9","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1182\/blood-2025-4503","article-title":"Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL)","volume":"146","author":"McGuirk","year":"2025","journal-title":"Blood"},{"issue":"suppl 13","key":"2026090811321228300_bib10","article-title":"Abstract LB-112: engineering AP1 to combat CAR T cell exhaustion","volume":"78","author":"Lynn","year":"2018","journal-title":"Cancer Res"},{"issue":"3","key":"2026090811321228300_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"27","key":"2026090811321228300_bib12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026090811321228300_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026090811321228300_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026090811321228300_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.14740\/wjon2534","article-title":"CD19 expression in B-cell lymphomas and clinical considerations in the evolving landscape of CD19-targeted therapy","volume":"16","author":"Marshalek","year":"2025","journal-title":"World J Oncol"},{"issue":"19","key":"2026090811321228300_bib16","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"2026090811321228300_bib17","doi-asserted-by":"crossref","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"key":"2026090811321228300_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2017.00004","article-title":"Significance of anti-HLA antibodies on adult and pediatric heart allograft outcomes","volume":"8","author":"Mangiola","year":"2017","journal-title":"Front Immunol"},{"issue":"6","key":"2026090811321228300_bib19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3324\/haematol.2015.141119","article-title":"How to select the best available related or unrelated donor of hematopoietic stem cells?","volume":"101","author":"Tiercy","year":"2016","journal-title":"Haematologica"},{"issue":"27","key":"2026090811321228300_bib20","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026090811321228300_bib21","volume-title":"YESCARTA\u2122 (axicabtagene ciloleucel) suspension for intravenous infusion [FDA-approved package insert]","year":"2025"},{"issue":"4","key":"2026090811321228300_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"26","key":"2026090811321228300_bib23","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"2026090811321228300_bib24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2026090811321228300_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090811321228300_bib26","first-page":"A1","article-title":"Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency","volume":"11","author":"Kalaitzidis","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"2026090811321228300_bib27","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2024-203563","article-title":"CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T cell with novel potency edits: data from phase 1 dose escalation study in patients with relapsed or refractory B-cell malignancies","volume":"144","author":"Ghobadi","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5778\/2541051\/blooda_adv-2026-020123-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5778\/2541051\/blooda_adv-2026-020123-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:19Z","timestamp":1788881539000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5778\/568185\/Safety-and-efficacy-of-allogeneic-CD19-directed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":27,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020123","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,26]]}}}